Report cover image

Global Alzheimer’s Agitation Clinical Treatment Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 107 Pages
SKU # APRC20353868

Description

Summary

According to APO Research, The global Alzheimer’s Agitation Clinical Treatment market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Alzheimer’s Agitation Clinical Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Alzheimer’s Agitation Clinical Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Alzheimer’s Agitation Clinical Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Alzheimer’s Agitation Clinical Treatment include Ono Pharmaceutical, AstraZeneca, Bristol Myers Squibb, Biogen, Otsuka Holdings, Glaxo Smith Kline, Pfizer, Eli Lilly and Company and H. Lundbeck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Alzheimer’s Agitation Clinical Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alzheimer’s Agitation Clinical Treatment.

The Alzheimer’s Agitation Clinical Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Alzheimer’s Agitation Clinical Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Alzheimer’s Agitation Clinical Treatment Segment by Company

Ono Pharmaceutical
AstraZeneca
Bristol Myers Squibb
Biogen
Otsuka Holdings
Glaxo Smith Kline
Pfizer
Eli Lilly and Company
H. Lundbeck
Novartis
Johnson and Johnson
Eisai

Alzheimer’s Agitation Clinical Treatment Segment by Type

Donepezil
Galantamine
Rivastigmine

Alzheimer’s Agitation Clinical Treatment Segment by Application

General Hospitals
Specialty Clinics

Alzheimer’s Agitation Clinical Treatment Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alzheimer’s Agitation Clinical Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alzheimer’s Agitation Clinical Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alzheimer’s Agitation Clinical Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alzheimer’s Agitation Clinical Treatment manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Alzheimer’s Agitation Clinical Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Table of Contents

107 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Alzheimer’s Agitation Clinical Treatment Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Alzheimer’s Agitation Clinical Treatment Sales Estimates and Forecasts (2020-2031)
1.3 Alzheimer’s Agitation Clinical Treatment Market by Type
1.3.1 Donepezil
1.3.2 Galantamine
1.3.3 Rivastigmine
1.4 Global Alzheimer’s Agitation Clinical Treatment Market Size by Type
1.4.1 Global Alzheimer’s Agitation Clinical Treatment Market Size Overview by Type (2020-2031)
1.4.2 Global Alzheimer’s Agitation Clinical Treatment Historic Market Size Review by Type (2020-2025)
1.4.3 Global Alzheimer’s Agitation Clinical Treatment Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Alzheimer’s Agitation Clinical Treatment Sales Breakdown by Type (2020-2025)
1.5.2 Europe Alzheimer’s Agitation Clinical Treatment Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Alzheimer’s Agitation Clinical Treatment Sales Breakdown by Type (2020-2025)
1.5.4 South America Alzheimer’s Agitation Clinical Treatment Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Alzheimer’s Agitation Clinical Treatment Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Alzheimer’s Agitation Clinical Treatment Industry Trends
2.2 Alzheimer’s Agitation Clinical Treatment Industry Drivers
2.3 Alzheimer’s Agitation Clinical Treatment Industry Opportunities and Challenges
2.4 Alzheimer’s Agitation Clinical Treatment Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Alzheimer’s Agitation Clinical Treatment Revenue (2020-2025)
3.2 Global Top Players by Alzheimer’s Agitation Clinical Treatment Sales (2020-2025)
3.3 Global Top Players by Alzheimer’s Agitation Clinical Treatment Price (2020-2025)
3.4 Global Alzheimer’s Agitation Clinical Treatment Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Alzheimer’s Agitation Clinical Treatment Major Company Production Sites & Headquarters
3.6 Global Alzheimer’s Agitation Clinical Treatment Company, Product Type & Application
3.7 Global Alzheimer’s Agitation Clinical Treatment Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Alzheimer’s Agitation Clinical Treatment Market CR5 and HHI
3.8.2 Global Top 5 and 10 Alzheimer’s Agitation Clinical Treatment Players Market Share by Revenue in 2024
3.8.3 2023 Alzheimer’s Agitation Clinical Treatment Tier 1, Tier 2, and Tier 3
4 Alzheimer’s Agitation Clinical Treatment Regional Status and Outlook
4.1 Global Alzheimer’s Agitation Clinical Treatment Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Alzheimer’s Agitation Clinical Treatment Historic Market Size by Region
4.2.1 Global Alzheimer’s Agitation Clinical Treatment Sales in Volume by Region (2020-2025)
4.2.2 Global Alzheimer’s Agitation Clinical Treatment Sales in Value by Region (2020-2025)
4.2.3 Global Alzheimer’s Agitation Clinical Treatment Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Alzheimer’s Agitation Clinical Treatment Forecasted Market Size by Region
4.3.1 Global Alzheimer’s Agitation Clinical Treatment Sales in Volume by Region (2026-2031)
4.3.2 Global Alzheimer’s Agitation Clinical Treatment Sales in Value by Region (2026-2031)
4.3.3 Global Alzheimer’s Agitation Clinical Treatment Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Alzheimer’s Agitation Clinical Treatment by Application
5.1 Alzheimer’s Agitation Clinical Treatment Market by Application
5.1.1 General Hospitals
5.1.2 Specialty Clinics
5.2 Global Alzheimer’s Agitation Clinical Treatment Market Size by Application
5.2.1 Global Alzheimer’s Agitation Clinical Treatment Market Size Overview by Application (2020-2031)
5.2.2 Global Alzheimer’s Agitation Clinical Treatment Historic Market Size Review by Application (2020-2025)
5.2.3 Global Alzheimer’s Agitation Clinical Treatment Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Alzheimer’s Agitation Clinical Treatment Sales Breakdown by Application (2020-2025)
5.3.2 Europe Alzheimer’s Agitation Clinical Treatment Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Alzheimer’s Agitation Clinical Treatment Sales Breakdown by Application (2020-2025)
5.3.4 South America Alzheimer’s Agitation Clinical Treatment Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Alzheimer’s Agitation Clinical Treatment Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Ono Pharmaceutical
6.1.1 Ono Pharmaceutical Comapny Information
6.1.2 Ono Pharmaceutical Business Overview
6.1.3 Ono Pharmaceutical Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Ono Pharmaceutical Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.1.5 Ono Pharmaceutical Recent Developments
6.2 AstraZeneca
6.2.1 AstraZeneca Comapny Information
6.2.2 AstraZeneca Business Overview
6.2.3 AstraZeneca Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.2.4 AstraZeneca Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.2.5 AstraZeneca Recent Developments
6.3 Bristol Myers Squibb
6.3.1 Bristol Myers Squibb Comapny Information
6.3.2 Bristol Myers Squibb Business Overview
6.3.3 Bristol Myers Squibb Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Bristol Myers Squibb Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.3.5 Bristol Myers Squibb Recent Developments
6.4 Biogen
6.4.1 Biogen Comapny Information
6.4.2 Biogen Business Overview
6.4.3 Biogen Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Biogen Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.4.5 Biogen Recent Developments
6.5 Otsuka Holdings
6.5.1 Otsuka Holdings Comapny Information
6.5.2 Otsuka Holdings Business Overview
6.5.3 Otsuka Holdings Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Otsuka Holdings Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.5.5 Otsuka Holdings Recent Developments
6.6 Glaxo Smith Kline
6.6.1 Glaxo Smith Kline Comapny Information
6.6.2 Glaxo Smith Kline Business Overview
6.6.3 Glaxo Smith Kline Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Glaxo Smith Kline Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.6.5 Glaxo Smith Kline Recent Developments
6.7 Pfizer
6.7.1 Pfizer Comapny Information
6.7.2 Pfizer Business Overview
6.7.3 Pfizer Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.7.5 Pfizer Recent Developments
6.8 Eli Lilly and Company
6.8.1 Eli Lilly and Company Comapny Information
6.8.2 Eli Lilly and Company Business Overview
6.8.3 Eli Lilly and Company Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Eli Lilly and Company Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.8.5 Eli Lilly and Company Recent Developments
6.9 H. Lundbeck
6.9.1 H. Lundbeck Comapny Information
6.9.2 H. Lundbeck Business Overview
6.9.3 H. Lundbeck Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.9.4 H. Lundbeck Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.9.5 H. Lundbeck Recent Developments
6.10 Novartis
6.10.1 Novartis Comapny Information
6.10.2 Novartis Business Overview
6.10.3 Novartis Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Novartis Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.10.5 Novartis Recent Developments
6.11 Johnson and Johnson
6.11.1 Johnson and Johnson Comapny Information
6.11.2 Johnson and Johnson Business Overview
6.11.3 Johnson and Johnson Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Johnson and Johnson Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.11.5 Johnson and Johnson Recent Developments
6.12 Eisai
6.12.1 Eisai Comapny Information
6.12.2 Eisai Business Overview
6.12.3 Eisai Alzheimer’s Agitation Clinical Treatment Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Eisai Alzheimer’s Agitation Clinical Treatment Product Portfolio
6.12.5 Eisai Recent Developments
7 North America by Country
7.1 North America Alzheimer’s Agitation Clinical Treatment Sales by Country
7.1.1 North America Alzheimer’s Agitation Clinical Treatment Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Alzheimer’s Agitation Clinical Treatment Sales by Country (2020-2025)
7.1.3 North America Alzheimer’s Agitation Clinical Treatment Sales Forecast by Country (2026-2031)
7.2 North America Alzheimer’s Agitation Clinical Treatment Market Size by Country
7.2.1 North America Alzheimer’s Agitation Clinical Treatment Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Alzheimer’s Agitation Clinical Treatment Market Size by Country (2020-2025)
7.2.3 North America Alzheimer’s Agitation Clinical Treatment Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Alzheimer’s Agitation Clinical Treatment Sales by Country
8.1.1 Europe Alzheimer’s Agitation Clinical Treatment Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Alzheimer’s Agitation Clinical Treatment Sales by Country (2020-2025)
8.1.3 Europe Alzheimer’s Agitation Clinical Treatment Sales Forecast by Country (2026-2031)
8.2 Europe Alzheimer’s Agitation Clinical Treatment Market Size by Country
8.2.1 Europe Alzheimer’s Agitation Clinical Treatment Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Alzheimer’s Agitation Clinical Treatment Market Size by Country (2020-2025)
8.2.3 Europe Alzheimer’s Agitation Clinical Treatment Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Alzheimer’s Agitation Clinical Treatment Sales by Country
9.1.1 Asia-Pacific Alzheimer’s Agitation Clinical Treatment Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Alzheimer’s Agitation Clinical Treatment Sales by Country (2020-2025)
9.1.3 Asia-Pacific Alzheimer’s Agitation Clinical Treatment Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Alzheimer’s Agitation Clinical Treatment Market Size by Country
9.2.1 Asia-Pacific Alzheimer’s Agitation Clinical Treatment Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Alzheimer’s Agitation Clinical Treatment Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Alzheimer’s Agitation Clinical Treatment Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Alzheimer’s Agitation Clinical Treatment Sales by Country
10.1.1 South America Alzheimer’s Agitation Clinical Treatment Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Alzheimer’s Agitation Clinical Treatment Sales by Country (2020-2025)
10.1.3 South America Alzheimer’s Agitation Clinical Treatment Sales Forecast by Country (2026-2031)
10.2 South America Alzheimer’s Agitation Clinical Treatment Market Size by Country
10.2.1 South America Alzheimer’s Agitation Clinical Treatment Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Alzheimer’s Agitation Clinical Treatment Market Size by Country (2020-2025)
10.2.3 South America Alzheimer’s Agitation Clinical Treatment Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Alzheimer’s Agitation Clinical Treatment Sales by Country
11.1.1 Middle East and Africa Alzheimer’s Agitation Clinical Treatment Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Alzheimer’s Agitation Clinical Treatment Sales by Country (2020-2025)
11.1.3 Middle East and Africa Alzheimer’s Agitation Clinical Treatment Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Alzheimer’s Agitation Clinical Treatment Market Size by Country
11.2.1 Middle East and Africa Alzheimer’s Agitation Clinical Treatment Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Alzheimer’s Agitation Clinical Treatment Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Alzheimer’s Agitation Clinical Treatment Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Alzheimer’s Agitation Clinical Treatment Value Chain Analysis
12.1.1 Alzheimer’s Agitation Clinical Treatment Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Alzheimer’s Agitation Clinical Treatment Production Mode & Process
12.2 Alzheimer’s Agitation Clinical Treatment Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Alzheimer’s Agitation Clinical Treatment Distributors
12.2.3 Alzheimer’s Agitation Clinical Treatment Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.